These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 309061)
1. [Long term effects of splenectomy on the immune-status of Hodgkin's disease patients depending on the modality of treatment (author's transl)]. Schaadt M; Diehl V; Kalden JR; Schmidt N; Laskewitz E Med Klin; 1978 Oct; 73(40):1381-8. PubMed ID: 309061 [TBL] [Abstract][Full Text] [Related]
2. [Proportions and absolute count of T- and B-lymphocytes in peripheral blood and their blastic transformation induced by mitogens in splenectomized and non-splenectomized patients with Hodgkin's disease]. Pluzańska A Acta Haematol Pol; 1978; 9(1):37-44. PubMed ID: 307325 [TBL] [Abstract][Full Text] [Related]
3. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578 [TBL] [Abstract][Full Text] [Related]
4. Long-term influence of splenectomy on immune functions in patients with Hodgkin's disease. Björkholm M; Askergren J; Holm G; Mellstedt H Scand J Haematol; 1980 Jan; 24(1):87-94. PubMed ID: 6966069 [TBL] [Abstract][Full Text] [Related]
5. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)]. Lang JM; Bigel P; Oberling F; Mayer S Pathol Biol (Paris); 1978; 26(3-4):159-62. PubMed ID: 355984 [TBL] [Abstract][Full Text] [Related]
6. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)]. Lang JM; Bigel P; Oberling F; Mayer S Sem Hop; 1978 Nov 8-15; 54(37-40):1155-8. PubMed ID: 217096 [TBL] [Abstract][Full Text] [Related]
7. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease. Levo Y; Rotter V; Ramot B Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352 [TBL] [Abstract][Full Text] [Related]
8. [The bone marrow in Hodgkin's disease following radiotherapy and splenectomy]. Baĭsogolov GD; Pavlov VV; Bogatyreva TI; Khait SE; Kuz'mina EG Med Radiol (Mosk); 1987 May; 32(5):3-7. PubMed ID: 3586920 [TBL] [Abstract][Full Text] [Related]
9. Subpopulations of human T lymphocytes in patients with Hodgkin's disease before and after treatment. Karande AA; Gulwani B; Advani SH; Gangal SG Neoplasma; 1982; 29(2):149-59. PubMed ID: 6981068 [TBL] [Abstract][Full Text] [Related]
10. B and T lymphocytes in Hodgkin's disease. Analysis at diagnosis and following therapy. Gajl-Peczalska KJ; Bloomfield CD; Sosin H; Kersey JH Clin Exp Immunol; 1976 Jan; 23(1):47-55. PubMed ID: 1083318 [TBL] [Abstract][Full Text] [Related]
11. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. Landgren O; Björkholm M; Konradsen HB; Söderqvist M; Nilsson B; Gustavsson A; Axdorph U; Kalin M; Grimfors G J Intern Med; 2004 Jun; 255(6):664-73. PubMed ID: 15147530 [TBL] [Abstract][Full Text] [Related]
12. [Effect of radiochemotherapy and splenectomy on lymphoid subclasses in patients with Hodgkin's lymphoma in complete remission]. Leoni P; Montroni M; Montillo M; Salvi A; Centurioni R; Fanciulli E G Clin Med; 1981 Oct; 62(10):685-92. PubMed ID: 6977469 [No Abstract] [Full Text] [Related]
13. [Immunglobulins G, A, M, and E in lymphogranulomatosis (author's transl)]. Steidle C; Fateh-Moghadam A; Lamerz R; Huhn D; Ehrhart H MMW Munch Med Wochenschr; 1976 Apr; 118(16):503-8. PubMed ID: 818517 [TBL] [Abstract][Full Text] [Related]
14. [Immunological data in the clinical evaluation of Hodgkin's diseases]. Burchardt K Z Gesamte Inn Med; 1981 Nov; 36(21):840. PubMed ID: 6977241 [TBL] [Abstract][Full Text] [Related]
15. Management of advanced Hodgkin's disease in remission. Klener P; Hausner P; Donner L Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):213-7. PubMed ID: 6179821 [TBL] [Abstract][Full Text] [Related]
16. [Questions and aspects of radiotherapy of adult patients with localized supradiaphragmatic stage (CS I/II) Hodgkin's disease. 1. Questions and aspects on indications for primary and adjuvant radiotherapy]. Glanzmann C; Lütolf UM Strahlenther Onkol; 1993 Aug; 169(8):449-58. PubMed ID: 8356505 [TBL] [Abstract][Full Text] [Related]
17. Impaired humoral immunity in treated Hodgkin's disease. Weitzman SA; Aisenberg AC; Siber GR; Smith DH N Engl J Med; 1977 Aug; 297(5):245-8. PubMed ID: 301608 [TBL] [Abstract][Full Text] [Related]
18. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens. Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984 [TBL] [Abstract][Full Text] [Related]
19. A micro-method for PHA-induced stimulation of human lymphocytes. II. communication: effect of splenectomy on the inhibitory activity of serum in patients with Hodgkin's disease. Pappas A; Pees H; Girmann G Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):1-10. PubMed ID: 868205 [TBL] [Abstract][Full Text] [Related]
20. Levamisole in the treatment of Hodgkin's disease. Berényi E; Kávai M; Szabolcsi M; Szegedi G Acta Med Acad Sci Hung; 1979; 36(2):177-85. PubMed ID: 317549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]